Trial Profile

A Master Protocol Phase I/II Study to Investigate Biomarker-Guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy for the Treatment of Participants With Advanced/Recurrent Ovarian Cancer (Ovarian Platform)

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I/II

Latest Information Update: 05 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Saruparib (Primary)
Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Focus Adverse reactions
Sponsors AstraZeneca

20 Feb 2026 Planned End Date changed from 27 Mar 2029 to 19 Dec 2025.
20 Feb 2026 Planned primary completion date changed from 27 Mar 2029 to 19 Dec 2025.
20 Feb 2026 Status changed from active, no longer recruiting to withdrawn prior to enrolment.Reason the study was stopped: The study termination is based on LSPC decision and is not related to any safety, efficacy or quality concerns.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com